Clinical research sites face a growing number of regulatory, technical, and administrative hurdles associated with maintaining compliance. The largest contributor is the increased scale and complexity of the modern protocol. Where once a study site conducted few, mostly static, protocols, today’s protocols evolve based on real-time data and bring together multiple specialized stakeholders across time zones and continents.
From this growth in complexity, the ability to produce documentation detailed enough to enable both the conduct of a clinical study and the quality of the data produced to be evaluated has overwhelmed regulators, sponsors, and, most of all, research sites.
Standardization represents a significant opportunity to improve record-keeping and simplify compliance at sites.
In 2009, sponsors and industry professionals discovered that ICH GCP’s list of essential documents did not provide a complete scope of the actual records managed in their trial master file (TMF), the sponsor’s key deliverable of the clinical study. Document nomenclature and filing conventions varied wildly across teams and organizations, and inconsistencies in structure from one TMF to another made it difficult to speak the same language, review quality and completeness, and evaluate potential mergers and acquisitions1. In 2011, the TMF Reference Model, also known as the Drug Information Association (DIA) Reference Model, was released. As sponsors and CROs digitized their records, the TMF Reference model was incorporated into document management and electronic trial master file (eTMF) systems to streamline adoption and simplify information exchange.
The TMF Reference Model is an industry-adopted structure for the TMF that takes the form of an index. This index provides a model of a complete TMF, which can then be customized as needed for a specific clinical study. The reference model assigns documents to a comprehensive taxonomy complete with standard nomenclature to enable consistent filing. Most TMF experts recommend the use of the reference model, but adoption is not mandatory for regulatory compliance.
While sponsors have enjoyed the benefits of the TMF reference model and eTMF systems, sites continue to execute each protocol without a standard model – and mostly on paper. The problem is exacerbated when sponsors enforce varying binder structures on sites. As a result, the investigator site file (ISF), also known as the site’s regulatory binder, has no standard taxonomy, is unique to each study site, and is often managed in paper medium. Without a standard, sites face increasing difficulty maintaining consistency and compliance across all of their studies.
Some suggest that imposing the TMF reference model on research sites is a solution. However, it is difficult for sites to adopt the reference model because it was developed primarily from a sponsor perspective; thus, it is much larger in scope than is necessary, and its terminology is not intuitive for sites.
Several industry groups, sponsors, and sites agree that a reference model for sites is needed. An ISF reference model will standardize filing structures and produce the following benefits:
The result would be improved efficiency, reduced regulatory risk, and better study outcomes—a clear win-win for all study stakeholders.
Because of the benefits of an ISF reference model, several draft models have been proposed in the last decade. Of the models that have gained greater attention, no one model has gained widespread use. The two most common weaknesses of the models include:
A reference model that meets the needs of sites, improves quality, and provides a path toward a better future, must be comprehensive enough to support a site’s transition into digital and purpose-built systems. Technology-based ISF solutions need to fully address the present and future needs of sites in order to add value.
“The purpose here is not to go to something that’s an ‘e’. The purpose is not to go into an eISF or some digital format. I could use Microsoft Word, that’s not an improvement. The purpose is to improve quality,” according to Jeff Kingsley, Founder and CEO of IACT Health.4
To achieve this goal, a more comprehensive reference model is needed and, at minimum, must contain the following elements:
Fundamentals
Collaborative Mapping
Key Attributes
The goal of a comprehensive model is not to increase complexity, but to achieve the long-term benefits of standardization, including increased quality, reduced regulatory risk, better visibility through reporting, and process automation, which will ultimately lead to happier sites and better study results.
Veeva believes an international, comprehensive eISF standard will allow research sites to better meet their regulatory obligations by freeing up precious resources and returning a site’s focus to what is most important: the thoughtful care of patients and the production of knowledge that heals.
To that end, we are releasing a free and publicly available eISF reference model. The Veeva eISF Reference Model was created based on feedback from the real-life needs of busy research sites and draws on our experience as an active member of the TMF Reference Model Steering Committee and the leader in document and data technology for the clinical research industry. The model is actively in use by sites across the globe and is immediately useful to any study site whether or not the site uses Veeva software.
Access the Veeva eISF Reference Model >
References:
1. Phlexglobal, 2019. 10 Short Years Ago, the TMF Reference Model Was Born.
2. FDA.gov, 2018. E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1) Guidance for Industry.
3. TMFRefModel.com, 2018. TMF Reference Model User Guide.
4. Jeff Kingsley, 2019. Empowering Sites to Do More with Less (Paper).